Search
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870ExperimentalIntegrins are important adhesion molecules that regulate tumor and endothelial cell survival, proliferation and migration. The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin ant...
Topsalysin
go.drugbank.com/drugs/DB05160InvestigationalTopsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
PTI-801
go.drugbank.com/drugs/DB05300InvestigationalIt is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointe...
Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolineFaxeladol
go.drugbank.com/drugs/DB20529InvestigationalEffect of Food on it). … Faxeladol is under investigation in clinical trial NCT03765801 (A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the
EVT 201
go.drugbank.com/drugs/DB05721InvestigationalEVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.
G305
go.drugbank.com/drugs/DB17292InvestigationalG305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.